Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

This study developed dutasteride-loaded microneedle systems using a specific polymer to enhance transdermal delivery, demonstrating efficient drug release and increased accumulation in hair follicles, thus supporting their potential for treating androgenic alopecia.

This study observed that DDAIP-HCl enhanced the permeation of minoxidil through human cadaver skin, suggesting potential for improved treatment efficacy in male pattern hair loss.

This study found that the newly developed microarray patches for intradermal delivery of finasteride showed high drug content and significantly improved skin deposition compared to existing methods.

This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.

This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

In this study, researchers developed a new method for producing dissolving microneedle array patches containing mesoporous silica nanoparticles, successfully confirming nanoparticle deposition and release in both ex vivo and in vivo models.

This study found that subcutaneous injection of medroxyprogesterone acetate was more effective than intramuscular or topical treatments in reducing hair diameter for hirsute females.

This study found that dexamethasone treatment inhibited the inflammatory response and the induction of ornithine decarboxylase activity in mouse skin after TPA application, although the effect on ODC was weaker during the hyperplastic stage.

This study found that the 15-PGDH inhibitor DPP improved endothelial function in hair-related cells exposed to DHT by reducing oxidative stress and enhancing angiogenic capacity.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

This study reports that progesterone metabolism to DHP and THP is necessary for its neuroprotective effect against kainic acid excitotoxicity in ovariectomized rats, unlike the synthetic progestin MPA.

Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.

In this study, most surveyed physicians were aware of the meningioma risk linked to cyproterone acetate monotherapy, but many did not recall receiving updated safety communications.

This study reported high analytical performance of an RMP for DHT quantification, with the ability to differentiate between 5α-DHT and 5β-DHT isomers, making it suitable for routine assay standardization and clinical sample evaluation.

This study found that dutasteride may offer neuroprotection in early-stage Parkinson's disease by preventing loss of striatal dopamine and altering steroid levels in MPTP-lesioned mice.

This study found that females exposed to high cumulative doses of cyproterone acetate had a 6–20 fold increased risk of developing meningiomas compared to those on lower doses.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This study found that a topical formulation containing DMG-Na significantly improved hair loss parameters in people experiencing hair loss, suggesting its potential effectiveness for such conditions.

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

LMWP-PDGFA shows promise for improving hair health and treating hair loss with fewer side effects.

This study found that biomimetic dermal papilla spheres cultured in a specific microenvironment can partially restore hair-inducing ability in high-passage dermal papilla cells in nude mice, resembling the characteristics of primary cells.

In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.

This study found that mycophenolic acid promotes dermal papilla cell proliferation and anagen hair follicle induction in mice, suggesting potential as a treatment for hair-loss disorders.

This study found that systemic administration of NDP-MSH, a melanocortin receptor agonist, provided neuroprotective effects on dopaminergic nigrostriatal neurons in a mouse model of Parkinson's disease, reducing neuroinflammation and suggesting a role for regulatory T cells in these neuroprotective effects.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

This study found that while dutasteride significantly altered pregnane metabolism in mares during late gestation, it did not impact pregnancy outcomes, highlighting the complexity of pregnane metabolism and the necessity of LC-MS/MS for accurate measurement.

This study found that cyclic MPA is as effective as OCPs in resuming ovulation among women with PCOS, offering a viable alternative for those who cannot or choose not to use OCPs.